Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Evaluation of Bone Marrow CD8 + tissue-Resident Memory T Cells in Multiple Myeloma

Melania Carlisi, MD, Salvatrice Mancuso, MD, Marco Pio La Manna, Biologist, Valentina Orlando, Biologist, Nadia Caccamo, Prof, Sergio Siragusa, Prof, MD

Blood (2019) 134 (Supplement_1): 4389.

https://doi.org/10.1182/blood-2019-131349

Published: 2019

Journal Articles

Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis

Pallavi Mehta, MD DM, Neha Yadav, BDS , MBA, Mohan Bhaarat, Sumeet Prakash Mirgh, MBBS, MDDM, Vishvdeep Khushoo, MBBS, MDDM, Shinto Francis Thekuddan, MBBS, MDDM, Narendra Agrawal, MD DM, Rayaz Ahmed, MDDM, Dinesh Bhurani, MD DM, FRCPA

Blood (2019) 134 (Supplement_1): 5572.

https://doi.org/10.1182/blood-2019-131674

Published: 2019

Journal Articles

Treatment of Multiple Myeloma Patients Progressing on Lenalidomide-Based Regimens

Donna E Reece, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Victor Jimenez-Zepeda, MD, Arleigh McCurdy, MD, Kevin Song, MD, Michael Sebag, MD PhD, Richard Leblanc, MDFRCPC, Martha L Louzada, MDMSc, Darrell J White, MD, Julie Stakiw, MD, Tony Reiman, MD, Rami Kotb, MD, Muhammad Aslam, MD, Engin Gul, BS, MBA, Christopher P Venner, MD

Blood (2019) 134 (Supplement_1): 1886.

https://doi.org/10.1182/blood-2019-125479

Published: 2019

Journal Articles

Efficacy of Bortezomib Based Regimens and Disease Monitoring in Light Chain Multiple Myeloma: A Review of Literature

Mustafa Nadeem Malik, MD, Abdul Rafae, MD, Shehroz Aslam, MD, Rida Riaz, MBBS, Seren Durer, MD, Ceren Durer, MD, Muhammad Abu Zar, MD, Zunairah Shah, MBBS, Ahmad Kamal, MD, Anum Qureshi, Jemin Aby Jose, MD, Insija Ilyas Selene, MBBS, Faiza Jamil, MD, Madeeha Shafqat, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5624.

https://doi.org/10.1182/blood-2018-99-109921

Published: 2018

Journal Articles

Bortezomib, Lenalidomide and Low-Dose Dexamethasone (VRD) Versus Lenalidomide and Low-Dose Dexamethasone (Ld) for Newly-Diagnosed Multiple Myeloma- a Randomized Phase III Study

Anjali Mookerjee, MBBS, Ritu Gupta, Shivali Jasrotia, PhD, Ranjit Sahoo, Rakesh Kumar, Sanjay Thulkar, Om Dutt Sharma, Lalit Kumar

Blood (2017) 130 (Supplement 1): 906.

https://doi.org/10.1182/blood.V130.Suppl_1.906.906

Published: 2017

Journal Articles

A Phase I/II Study of Pomalidomide and Dexamethasone with Growth Factor Support in Patients with Relapsed/Refractory Multiple Myeloma

Elisabet E. Manasanch, MD, Hans C. Lee, MD, Krina K. Patel, MDMSc, Donna M. Weber, MD, Hun Ju Lee, MD, Sheeba K. Thomas, MD, Wendy Chen, MD, Onyeka Oriabure, Maria Badillo, Vivian Graham, Feng Lei, MS, Magda S McCarthy, Robert Z. Orlowski, MD PhD, Michael Wang, MD

Blood (2017) 130 (Supplement 1): 3090.

https://doi.org/10.1182/blood.V130.Suppl_1.3090.3090

Published: 2017

Journal Articles

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

Blood (2016) 128 (25): 2941–2948.

https://doi.org/10.1182/blood-2016-07-726778

Published: 2016

Journal Articles

Efficacy and Safety of Melphalan 140mg/m 2 Conditioned Autologous Stem Cell Transplantation in Elderly Pre-Dialysis and Dialysis Patients with Multiple Myeloma

Hatem Ali, MBBS, Baharani Jyoti, MBBS, FRCP, Shankaranarayana Paneesha, MD, Richard Lovell, Alex George Kanellopoulos, MD, Evgenia Xenou, MD, Iman Qureshi, MBBS, MRCP, Lorna Cain, Maria Kaparou, David John Sutton, MBBChir, MRCP, BSc, Rebecca Pryor, MB, MRCP, Emmanouil Nikolousis, PhDMBBS,FRCPath,MBA, Bhuvan Kishore, MBBS, MRCP, FRCPath

Blood (2016) 128 (22): 5822.

https://doi.org/10.1182/blood.V128.22.5822.5822

Published: 2016

Journal Articles

Early Monoclonal Para Protein Reduction and Response in Multiple Myeloma (EMPEROR study)

Ashish Kumar Panigrahi, MBBS, William E. P. Renwick, MBBS, FRACP, FRCPA, Duncan P. Carradice, MBBS, FRCPA, FRACP, PhD, Andrew Lim, MBBS, FRACP, FRCPA, Eleni Hatzis, MBBS

Blood (2016) 128 (22): 5707.

https://doi.org/10.1182/blood.V128.22.5707.5707

Published: 2016

Journal Articles

Immunologic Status Evaluated By the Absolute Lymphocyte/Monocyte Ratio Provides a Powerful Prognostic Tool for Newly Diagnosed Multiple Myeloma

Ehsan Malek, MD, Talib Dosani, MD, Raisa Pinto, MD, Fahrettin Covut, MD, Hugo Akabane, MD, James J. Driscoll, MD PhD, Marcos De Lima, MD

Blood (2016) 128 (22): 1862.

https://doi.org/10.1182/blood.V128.22.1862.1862

Published: 2016

Journal Articles

Report of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection in Four Patients with Hematological Malignancies Treated at King Fahad Medical City, Riyadh, Saudi Arabia

Ibraheem H Motabi, MRCP MD, Syed Ziauddin A. Zaidi, MBBS, FRCP, FCPS, FRCPath, FACP, Mamoun Hassan Ibrahim, MBBS, MRCPI, SBAH, Imran K Tailor, MBBS, MD FRCP, FRCPath, Nawal Faiez Alshehry, MD SBIM, SBAH, Mubarak S. AlGhamdi, MD, Shahid Iqbal, MBBS, FCPS, MRCP, Samer Mudaibigh, MD SBIM, SBAH, Fouad H Alnajjar, PharmD, MSc, BCOP

Blood (2016) 128 (22): 4903.

https://doi.org/10.1182/blood.V128.22.4903.4903

Published: 2016

Journal Articles

Serum Free Light Chain Responses Have Greater Concordance with Clinical Outcomes Than Those Assessed By Urine Electrophoresis in Light Chain Multiple Myeloma Patients

Thomas Dejoie, PharmD, Michel Attal, Philippe Moreau, Herve Avet-Loiseau, MD PhD

Blood (2016) 128 (22): 376.

https://doi.org/10.1182/blood.V128.22.376.376

Published: 2016

Journal Articles

Nontransplant Treatment Outcomes with Generic Novel Agents in Newly Diagnosed Multiple Myeloma Patients

Chandran K Nair, MD, Vineetha Raghavan, MD, Atanu Bhattacharjee, PhD, Satheesh Babu, MD, Sangeetha Nayanar, MD

Blood (2015) 126 (23): 5382.

https://doi.org/10.1182/blood.V126.23.5382.5382

Published: 2015

Journal Articles

Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant

Koji Sasaki, MD, Nina Shah, MD, Qaiser Bashir, MD, Chitra M. Hosing, MD, Uday R. Popat, MD, Yago Nieto, MD PhD, Simrit Parmar, MD, Jatin J. Shah, MD, Donna Weber, MD, Daniel Weissinger, Sheeba K. Thomas, MD, Robert Z. Orlowski, MD PhD, Richard E. Champlin, MD, Muzaffar H. Qazilbash, MD

Blood (2015) 126 (23): 3194.

https://doi.org/10.1182/blood.V126.23.3194.3194

Published: 2015

Journal Articles

Serum Free Light Chains Should be the Target of Response Evaluation in Light Chain Multiple Myeloma Rather Than Urines: Results from the IFM/DFCI 2009 Trial

Jill Corre, PharmD, PhD, Thomas Dejoie, PharmD, Helene Caillon, PharmD, Michel Attal, MD, Herve Avet-Loiseau, Philippe Moreau, MD

Blood (2014) 124 (21): 180.

https://doi.org/10.1182/blood.V124.21.180.180

Published: 2014

Journal Articles

Quantitative Assay of Immunoglobulin Free Light Chains (FLC): Evaluation of Monoclonal Versus Polyclonal Antibody and Immunoturbidimetric Versus Immunonephelometric Detection Technology

Dragana Segulja, Danica Matisic, PhD, Dunja Rogic, Andrea Tesija Kuna, Ines Vukasovic, Nada Vrkic, Josip Batinic, MD, Damir Nemet, MD PhD

Blood (2014) 124 (21): 5680.

https://doi.org/10.1182/blood.V124.21.5680.5680

Published: 2014

Journal Articles

Lenalidomide and Dexamethasone for Acute Light Chain-Induced Renal Failure: Final Results of a Phase II Study

Heinz Ludwig, Univ. Prof. Dr., Elisabeth Rauch, Thomas Kuehr, MD, Adam Zdenek, MD, Adalbert Weissmann, MD, Hedwig Kasparu, MD, Eva-Maria Autzinger, MD, Daniel Heintel, MD, Richard Greil, MD, Wolfram Poenisch, MD, Niklas Zojer, MD, Ercan Müldür, MD

Blood (2014) 124 (21): 3484.

https://doi.org/10.1182/blood.V124.21.3484.3484

Published: 2014

Journal Articles

Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?

Blood (2013) 122 (21): 1866.

https://doi.org/10.1182/blood.V122.21.1866.1866

Published: 2013

Journal Articles

Observations On Eosinophil Ifiltrates in The Bone Marrow Of Patients With Multiple Myeloma. Clinicopathological Correlates

Finella MC Brito-Babapulle, FRCPATH, Tanya Cranfield, MD, FRCP, Robert B Corser, FRCPath, Helen Dignum, Christopher James, FRCPAth, Mary Ganczakowski, FRCPath

Blood (2013) 122 (21): 5338.

https://doi.org/10.1182/blood.V122.21.5338.5338

Published: 2013

Journal Articles

Clonal Evolution In Two Multiple Myeloma Patients and a Biclonal MGUS Patient

Maria Kraj, Kelly Endean, Barbara Kruk, Krzysztof Warzocha, MD, PhD, Stephen Harding, Monika Dabrowska

Blood (2013) 122 (21): 5351.

https://doi.org/10.1182/blood.V122.21.5351.5351

Published: 2013

NARROW

Evaluation of Bone Marrow CD8 + tissue-Resident Memory T Cells in Multiple Myeloma

Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis

Treatment of Multiple Myeloma Patients Progressing on Lenalidomide-Based Regimens

Efficacy of Bortezomib Based Regimens and Disease Monitoring in Light Chain Multiple Myeloma: A Review of Literature

Bortezomib, Lenalidomide and Low-Dose Dexamethasone (VRD) Versus Lenalidomide and Low-Dose Dexamethasone (Ld) for Newly-Diagnosed Multiple Myeloma- a Randomized Phase III Study

A Phase I/II Study of Pomalidomide and Dexamethasone with Growth Factor Support in Patients with Relapsed/Refractory Multiple Myeloma

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

Efficacy and Safety of Melphalan 140mg/m 2 Conditioned Autologous Stem Cell Transplantation in Elderly Pre-Dialysis and Dialysis Patients with Multiple Myeloma

Early Monoclonal Para Protein Reduction and Response in Multiple Myeloma (EMPEROR study)

Immunologic Status Evaluated By the Absolute Lymphocyte/Monocyte Ratio Provides a Powerful Prognostic Tool for Newly Diagnosed Multiple Myeloma

Report of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection in Four Patients with Hematological Malignancies Treated at King Fahad Medical City, Riyadh, Saudi Arabia

Serum Free Light Chain Responses Have Greater Concordance with Clinical Outcomes Than Those Assessed By Urine Electrophoresis in Light Chain Multiple Myeloma Patients

Nontransplant Treatment Outcomes with Generic Novel Agents in Newly Diagnosed Multiple Myeloma Patients

Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant

Serum Free Light Chains Should be the Target of Response Evaluation in Light Chain Multiple Myeloma Rather Than Urines: Results from the IFM/DFCI 2009 Trial

Quantitative Assay of Immunoglobulin Free Light Chains (FLC): Evaluation of Monoclonal Versus Polyclonal Antibody and Immunoturbidimetric Versus Immunonephelometric Detection Technology

Lenalidomide and Dexamethasone for Acute Light Chain-Induced Renal Failure: Final Results of a Phase II Study

Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?

Observations On Eosinophil Ifiltrates in The Bone Marrow Of Patients With Multiple Myeloma. Clinicopathological Correlates

Clonal Evolution In Two Multiple Myeloma Patients and a Biclonal MGUS Patient

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only